Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

53 54 Next >

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

February 27, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

Via Newsfile

Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment ↗

February 26, 2024

The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks.

Via Investor's Business Daily

This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies ↗

February 26, 2024

Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increased tolerance in patients aged 1-55. FDA-approved expanded use for...

Via Benzinga

5 Tips to Manage Heart Health After a Heart Attack

February 23, 2024

(BPT) - By Dr. Norman Lepor

Via Brandpoint

Looking Into Novartis's Recent Short Interest ↗

February 22, 2024

Via Benzinga

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

Move Over Magnificent 7, Say Hello to the GRANOLAS ↗

February 22, 2024

Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.

Via InvestorPlace

Exit Now! 3 Biotech Stocks to Sell in February 2024 ↗

February 21, 2024

These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.

Via InvestorPlace

22 Blue-Chip European Dividend Growth Stocks ↗

February 16, 2024

A discussion of insights on European dividend growth stocks.

Via Talk Markets

What The Future Holds For Google's 'Other Bets' ↗

February 16, 2024

Alphabet's far-ranging Other Bets tickle imaginations, but they've piled up huge losses. Google stock could benefit as discipline is imposed.

Via Investor's Business Daily

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗

February 15, 2024

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

Via InvestorPlace

The 3 Biotech Stocks That Could Make Your February Unforgettable ↗

February 15, 2024

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

Via InvestorPlace

Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says ↗

February 14, 2024

Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties.

Via Benzinga

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

February 14, 2024

From Erasca, Inc.

Via GlobeNewswire

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales

February 13, 2024

Via Investor Brand Network

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month ↗

February 08, 2024

Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.

Via Investor's Business Daily

JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point ↗

February 06, 2024

BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target.

Via Benzinga

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B ↗

February 06, 2024

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.

Via Benzinga

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion ↗

February 05, 2024

Novartis will add to its cancer treatment pipeline with via the German biotech.

Via Investor's Business Daily

Drug Maker AbbVie Stock Sees RS Rating Jump To 81 ↗

February 05, 2024

AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81.

Via Investor's Business Daily

Why Is MorphoSys (MOR) Stock Up 50% Today? ↗

February 05, 2024

News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.

Via InvestorPlace

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer ↗

February 05, 2024

Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold...

Via Benzinga

3 Fabulous Dividend Stocks to Buy in February ↗

February 04, 2024

These stocks offer great dividends and more.

Via The Motley Fool

Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗

February 02, 2024

The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.

Via Benzinga

Topics Economy

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗

February 02, 2024

The Dow led the major indexes higher. Big techs diverged on results.

Via Investor's Business Daily

Topics Economy Stocks

Novartis Ag (NVS) Q4 2023 Earnings Call Transcript ↗

January 31, 2024

NVS earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 31, 2024

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on...

Via Benzinga

Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections ↗

January 31, 2024

Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired.

Via Investor's Business Daily

Why Is European Pharma Giant Novartis Stock Trading Lower Today? ↗

January 31, 2024

Novartis Q4 2023 sales reach $11.42 billion, up 8%. Strong growth in key drugs, Entresto, Kisqali, Kesimpta, Cosentyx, and Pluvicto. Core operating income at $3.8 billion.

Via Benzinga

Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser ↗

January 31, 2024

The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.

Via Benzinga

Topics Economy

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today